GLP-1 receptor agonists as multisystem therapies: from glycemic control to cardiorenal, neuroimmune, and metabolic disease
Malek Zarei, Yasamin Hajiani · 2026
Read GLP-1 receptor agonists as multisystem therapies: from glycemic control to cardiorenal, neuroimmune, and metabolic disease by Malek Zarei, Yasamin Hajiani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13479717.txt.
Description
Malek Zarei and Yasamin Hajiani published a 2026 narrative review of GLP-1 receptor agonists, the diabetes drugs now reshaping obesity and heart care. First built for blood sugar control, these medicines have accumulated outcome evidence far beyond glucose. The authors gathered randomized trials, heart and kidney outcome studies, meta-analyses, and real-world data, plus mechanism studies where helpful.
Trials consistently show meaningful weight loss and fewer major cardiovascular events. Kidney disease progression slows in people with and without diabetes. The review appraises how certain each benefit is, noting where study designs or mixed populations weaken confidence. Benefits appear only partly explained by weight and sugar changes, which raises fresh questions about direct effects on vessels, kidney, brain, and immune function.
Catalog record
| CREATOR | Malek Zarei, Yasamin Hajiani |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 113640 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |